{"schema_version":"1.0","type":"article","title":"從每天一顆藥到工廠訂單：口服環肽的錢，誰賺得到？","url":"https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026.md","lang":"zh-Hant","date":"2026-10-05","publish_at":"2026-10-05T08:00:00+08:00","updated_at":"2026-10-05","category":"商業分析系列","topic":"商業分析系列","tags":["口服環肽","enlicitide","Orbis","Novo Nordisk","製程"],"summary":"2026年9月17日，諾和諾德（Novo Nordisk）與Orbis Medicines宣布合作，開發心血管代謝疾病的口服大環肽。前期款與可能達成的開發、商業里程碑合計最高14億美元，另計銷售權利金，Novo亦將策略投資Orbis。大藥廠正在買新的藥物發現機會；這筆上限金額，還不是原料工廠手上的訂單，公告也未披露商業採購量或供應商。","key_points":[],"facts":[],"sections":[],"references":[{"title":"Orbis／Novo：口服大環肽合作公告（2026-09-17","source":"","date":"","url":""},{"title":"https://www.orbismedicines.com/news/orbis-medicines-enters-multi-target-drug-discovery-partnership-with-novo-nordisk-worth-up-to-usd-14-billion","source":"","date":"","url":"https://www.orbismedicines.com/news/orbis-medicines-enters-multi-target-drug-discovery-partnership-with-novo-nordisk-worth-up-to-usd-14-billion"},{"title":"FDA：Lipfendra核准信（NDA 220848）（FDA簽署2026-07-15","source":"","date":"","url":""},{"title":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220848Orig1s000ltr.pdf","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220848Orig1s000ltr.pdf"},{"title":"FDA：Lipfendra正式標籤（Revised 2026-07","source":"","date":"","url":""},{"title":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220848Orig1s000lbl.pdf","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220848Orig1s000lbl.pdf"},{"title":"JACS：Enlicitide癸酸鹽全合成原始論文（2025-03-24","source":"","date":"","url":""},{"title":"https://doi.org/10.1021/jacs.4c15966","source":"","date":"","url":"https://doi.org/10.1021/jacs.4c15966"},{"title":"Science：Enlicitide生物催化製造研究摘要（2026-05-07","source":"","date":"","url":""},{"title":"https://pubmed.ncbi.nlm.nih.gov/42096573/","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/42096573/"},{"title":"FDA／ICH Q7：原料藥GMP產業指引（2016-09，Revision 1","source":"","date":"","url":""},{"title":"https://www.fda.gov/media/71518/download","source":"","date":"","url":"https://www.fda.gov/media/71518/download"},{"title":"台灣神隆：胜肽合成與製程服務（頁面未標發布日；查閱2026-09-27","source":"","date":"","url":""},{"title":"https://www.scinopharm.com/tw/products-detail/54/","source":"","date":"","url":"https://www.scinopharm.com/tw/products-detail/54/"},{"title":"Merck：Lipfendra核准公告（2026-07-16","source":"","date":"","url":""},{"title":"https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/","source":"","date":"","url":"https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/"},{"title":"S4原論文全文公開鏡像（Aarhus大學伺服器","source":"","date":"","url":""},{"title":"https://maillist.au.dk/hyperkitty/list/hauser.chem%40maillist.au.dk/message/RWSJBSY53CCDATJCHCKPUXW4QBJVKMR3/attachment/6/total-synthesis-of-enlicitide-decanoate.pdf","source":"","date":"","url":"https://maillist.au.dk/hyperkitty/list/hauser.chem%40maillist.au.dk/message/RWSJBSY53CCDATJCHCKPUXW4QBJVKMR3/attachment/6/total-synthesis-of-enlicitide-decanoate.pdf"}],"images":[{"alt":"無刻痕橢圓錠、日曆與假設人群連到用量計算；20毫克enlicitide與22.21毫克癸酸鹽之間有等值橋接，對應60及66.63公斤的不同質量口徑。","url":"https://drugnews.com.tw/assets/articles/cyclic-peptide-upstream-2026/FIG01_ZH_R2.png"},{"alt":"連接完成的前驅物分別通往環化產物及不需要的寡聚物；高稀釋槽內保留同一類連接前驅物，只改變分子間距離，旁列溶劑與設備使用。","url":"https://drugnews.com.tw/assets/articles/cyclic-peptide-upstream-2026/FIG02_ZH_R3.png"},{"alt":"工程化酵素協助片段形成、連接及大環化，之後以結晶分離產物；「無保護基」限定於這些組裝步驟，步驟減少與商業成本分開標示。","url":"https://drugnews.com.tw/assets/articles/cyclic-peptide-upstream-2026/FIG03_ZH_R4.png"},{"alt":"中性合約連到產品需求、交付產能、製程品質及客戶對供應商的資格認證；下方分列研發服務與材料供應，對應不同收費安排。","url":"https://drugnews.com.tw/assets/articles/cyclic-peptide-upstream-2026/FIG04_ZH_R2.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/cyclic-peptide-upstream-2026/FIG01_ZH_R2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-05）。從每天一顆藥到工廠訂單：口服環肽的錢，誰賺得到？。https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-10-05-cyclic-peptide-upstream-2026-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}